Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores.

Gevaert T, Van Eycke YR, Vanden Broeck T, Van Poppel H, Salmon I, Rorive S, Claessens F, De Ridder D, Decaestecker C, Joniau S.

Sci Rep. 2018 Sep 25;8(1):14326. doi: 10.1038/s41598-018-32711-9.

2.

UCA1 overexpression is associated with less aggressive subtypes of bladder cancer.

Lebrun L, Milowich D, Le Mercier M, Allard J, Van Eycke YR, Roumeguere T, Decaestecker C, Salmon I, Rorive S.

Oncol Rep. 2018 Nov;40(5):2497-2506. doi: 10.3892/or.2018.6697. Epub 2018 Sep 10.

3.

Segmentation of glandular epithelium in colorectal tumours to automatically compartmentalise IHC biomarker quantification: A deep learning approach.

Van Eycke YR, Balsat C, Verset L, Debeir O, Salmon I, Decaestecker C.

Med Image Anal. 2018 Oct;49:35-45. doi: 10.1016/j.media.2018.07.004. Epub 2018 Jul 12.

PMID:
30081241
4.

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.

Tosco L, Laenen A, Gevaert T, Salmon I, Decaestecker C, Davicioni E, Buerki C, Claessens F, Swinnen J, Goffin K, Oyen R, Everaerts W, Moris L, De Meerleer G, Haustermans K, Joniau S; P.E.A.R.L. (ProstatE cAncer Research Leuven).

BMC Cancer. 2018 Apr 2;18(1):354. doi: 10.1186/s12885-018-4275-z.

5.

A prospective clinical study of the implications of IL-8 in the diagnosis, aggressiveness and prognosis of prostate cancer.

Roumeguère T, Legrand F, Rassy EE, Kaitouni MI, Albisinni S, Rousseau A, Vanhaeverbeek M, Rorive S, Decaestecker C, Debeir O, Boudjeltia KZ, Aoun F.

Future Sci OA. 2017 Nov 15;4(2):FSO266. doi: 10.4155/fsoa-2017-0084. eCollection 2018 Feb.

6.

Regulatory T cells constrain the TCR repertoire of antigen-stimulated conventional CD4 T cells.

Fontaine M, Vogel I, Van Eycke YR, Galuppo A, Ajouaou Y, Decaestecker C, Kassiotis G, Moser M, Leo O.

EMBO J. 2018 Feb 1;37(3):398-412. doi: 10.15252/embj.201796881. Epub 2017 Dec 20.

PMID:
29263148
7.

Galectin-1 is a diagnostic marker involved in thyroid cancer progression.

Arcolia V, Journe F, Wattier A, Leteurtre E, Renaud F, Gabius HJ, Remmelink M, Decaestecker C, Rodriguez A, Boutry S, Laurent S, Saussez S.

Int J Oncol. 2017 Sep;51(3):760-770. doi: 10.3892/ijo.2017.4065. Epub 2017 Jul 4.

8.

Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K.

Mod Pathol. 2017 Sep;30(9):1204-1212. doi: 10.1038/modpathol.2017.43. Epub 2017 Jun 16.

9.

ADAM-17/FHL2 colocalisation suggests interaction and role of these proteins in colorectal cancer.

Verset L, Tommelein J, Decaestecker C, De Vlieghere E, Bracke M, Salmon I, De Wever O, Demetter P.

Tumour Biol. 2017 Mar;39(3):1010428317695024. doi: 10.1177/1010428317695024.

PMID:
28349819
10.

Image processing in digital pathology: an opportunity to solve inter-batch variability of immunohistochemical staining.

Van Eycke YR, Allard J, Salmon I, Debeir O, Decaestecker C.

Sci Rep. 2017 Feb 21;7:42964. doi: 10.1038/srep42964.

11.

Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.

Descamps G, Karaca Y, Lechien JR, Kindt N, Decaestecker C, Remmelink M, Larsimont D, Andry G, Hassid S, Rodriguez A, Khalife M, Journe F, Saussez S.

J Cancer Res Clin Oncol. 2016 Oct;142(10):2185-96. doi: 10.1007/s00432-016-2203-7. Epub 2016 Jul 1.

12.

High-throughput analysis of tissue-based biomarkers in digital pathology.

Van Eycke YR, Debeir O, Verset L, Demetter P, Salmon I, Decaestecker C.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:7732-5. doi: 10.1109/EMBC.2015.7320184.

PMID:
26738084
13.

IGF-IR: a new prognostic biomarker for human glioblastoma.

Maris C, D'Haene N, Trépant AL, Le Mercier M, Sauvage S, Allard J, Rorive S, Demetter P, Decaestecker C, Salmon I.

Br J Cancer. 2015 Sep 1;113(5):729-37. doi: 10.1038/bjc.2015.242. Epub 2015 Aug 20.

14.

Diagnostic value of the UCA1 test for bladder cancer detection: a clinical study.

Milowich D, Le Mercier M, De Neve N, Sandras F, Roumeguere T, Decaestecker C, Salmon I, Rorive S.

Springerplus. 2015 Jul 16;4:349. doi: 10.1186/s40064-015-1092-6. eCollection 2015.

15.

Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis.

De Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, Van Cutsem E, Prenen H, Tejpar S, Spaepen M, Matthijs G, Decaestecker C, Moles Lopez X, Demetter P, Salmon I, Sagaert X.

Br J Cancer. 2015 Jul 28;113(3):500-9. doi: 10.1038/bjc.2015.213. Epub 2015 Jun 11.

16.

Impact of neoadjuvant therapy on cancer-associated fibroblasts in rectal cancer.

Verset L, Tommelein J, Moles Lopez X, Decaestecker C, Boterberg T, De Vlieghere E, Salmon I, Mareel M, Bracke M, De Wever O, Demetter P.

Radiother Oncol. 2015 Sep;116(3):449-54. doi: 10.1016/j.radonc.2015.05.007. Epub 2015 May 25.

PMID:
26021554
17.

Morphometric and quantitative immunohistochemical analysis of disease-related changes in the upper (suburothelial) lamina propria of the human bladder dome.

Gevaert T, Moles Lopez X, Sagaert X, Libbrecht L, Roskams T, Rorive S, Decaestecker C, Salmon I, De Ridder D.

PLoS One. 2015 May 14;10(5):e0127020. doi: 10.1371/journal.pone.0127020. eCollection 2015.

18.

An open data ecosystem for cell migration research.

Masuzzo P, Martens L; 2014 Cell Migration Workshop Participants, Ampe C, Anderson KI, Barry J, De Wever O, Debeir O, Decaestecker C, Dolznig H, Friedl P, Gaggioli C, Geiger B, Goldberg IG, Horn E, Horwitz R, Kam Z, Le Dévédec SE, Vignjevic DM, Moore J, Olivo-Marin JC, Sahai E, Sansone SA, Sanz-Moreno V, Strömblad S, Swedlow J, Textor J, Van Troys M, Zantl R.

Trends Cell Biol. 2015 Feb;25(2):55-8. doi: 10.1016/j.tcb.2014.11.005. Epub 2014 Dec 5.

PMID:
25484346
19.

Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms.

Trépant AL, Bouchart C, Rorive S, Sauvage S, Decaestecker C, Demetter P, Salmon I.

Tumour Biol. 2015 Mar;36(3):1943-53. doi: 10.1007/s13277-014-2800-5. Epub 2014 Nov 12.

PMID:
25384509
20.

Immunohistochemical toolkit for tracking and quantifying xenotransplanted human stem cells.

Allard J, Li K, Lopez XM, Blanchard S, Barbot P, Rorive S, Decaestecker C, Pochet R, Bohl D, Lepore AC, Salmon I, Nicaise C.

Regen Med. 2014;9(4):437-52. doi: 10.2217/rme.14.26.

21.

Registration of whole immunohistochemical slide images: an efficient way to characterize biomarker colocalization.

Moles Lopez X, Barbot P, Van Eycke YR, Verset L, Trépant AL, Larbanoix L, Salmon I, Decaestecker C.

J Am Med Inform Assoc. 2015 Jan;22(1):86-99. doi: 10.1136/amiajnl-2014-002710. Epub 2014 Aug 14.

22.

Helicase-like transcription factor: a new marker of well-differentiated thyroid cancers.

Arcolia V, Paci P, Dhont L, Chantrain G, Sirtaine N, Decaestecker C, Remmelink M, Belayew A, Saussez S.

BMC Cancer. 2014 Jul 8;14:492. doi: 10.1186/1471-2407-14-492.

23.

Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer.

Richard V, Kindt N, Decaestecker C, Gabius HJ, Laurent G, Noël JC, Saussez S.

Oncol Rep. 2014 Aug;32(2):523-9. doi: 10.3892/or.2014.3272. Epub 2014 Jun 16.

24.

Galectins and neovascularization in central nervous system tumors.

D'Haene N, Maris C, Rorive S, Decaestecker C, Le Mercier M, Salmon I.

Glycobiology. 2014 Oct;24(10):892-8. doi: 10.1093/glycob/cwu049. Epub 2014 May 26. Review.

PMID:
24861052
25.

Galectin fingerprinting in naso-sinusal diseases.

Duray A, De Maesschalck T, Decaestecker C, Remmelink M, Chantrain G, Neiveyans J, Horoi M, Leroy X, Gabius HJ, Saussez S.

Oncol Rep. 2014 Jul;32(1):23-32. doi: 10.3892/or.2014.3213. Epub 2014 May 23.

26.

Delineation of EFTUD2 haploinsufficiency-related phenotypes through a series of 36 patients.

Lehalle D, Gordon CT, Oufadem M, Goudefroye G, Boutaud L, Alessandri JL, Baena N, Baujat G, Baumann C, Boute-Benejean O, Caumes R, Decaestecker C, Gaillard D, Goldenberg A, Gonzales M, Holder-Espinasse M, Jacquemont ML, Lacombe D, Manouvrier-Hanu S, Marlin S, Mathieu-Dramard M, Morin G, Pasquier L, Petit F, Rio M, Smigiel R, Thauvin-Robinet C, Vasiljevic A, Verloes A, Malan V, Munnich A, de Pontual L, Vekemans M, Lyonnet S, Attié-Bitach T, Amiel J.

Hum Mutat. 2014 Apr;35(4):478-85. doi: 10.1002/humu.22517. Epub 2014 Mar 5.

PMID:
24470203
27.

An automated blur detection method for histological whole slide imaging.

Moles Lopez X, D'Andrea E, Barbot P, Bridoux AS, Rorive S, Salmon I, Debeir O, Decaestecker C.

PLoS One. 2013 Dec 13;8(12):e82710. doi: 10.1371/journal.pone.0082710. eCollection 2013.

28.

Polymerase chain reaction for Enterococcus faecalis in drain fluid: the first screening test for symptomatic colorectal anastomotic leakage. The Appeal-study: analysis of parameters predictive for evident anastomotic leakage.

Komen N, Slieker J, Willemsen P, Mannaerts G, Pattyn P, Karsten T, de Wilt H, van der Harst E, van Leeuwen W, Decaestecker C, Jeekel H, Lange JF.

Int J Colorectal Dis. 2014 Jan;29(1):15-21.

PMID:
24122105
29.

A masked PY-NLS in Drosophila TIS11 and its mammalian homolog tristetraprolin.

Twyffels L, Wauquier C, Soin R, Decaestecker C, Gueydan C, Kruys V.

PLoS One. 2013 Aug 9;8(8):e71686. doi: 10.1371/journal.pone.0071686. eCollection 2013.

30.

VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis.

D'Haene N, Sauvage S, Maris C, Adanja I, Le Mercier M, Decaestecker C, Baum L, Salmon I.

PLoS One. 2013 Jun 17;8(6):e67029. doi: 10.1371/journal.pone.0067029. Print 2013.

31.

Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer.

Verset L, Tommelein J, Moles Lopez X, Decaestecker C, Mareel M, Bracke M, Salmon I, De Wever O, Demetter P.

Br J Cancer. 2013 Jul 9;109(1):114-20. doi: 10.1038/bjc.2013.290. Epub 2013 Jun 11.

32.

Human papillomavirus predicts the outcome following concomitant chemoradiotherapy in patients with head and neck squamous cell carcinomas.

Duray A, Descamps G, Decaestecker C, Sirtaine N, Gilles A, Khalifé M, Chantrain G, Depuydt CE, Delvenne P, Saussez S.

Oncol Rep. 2013 Jul;30(1):371-6. doi: 10.3892/or.2013.2415. Epub 2013 Apr 22.

PMID:
23603900
33.

Sleep spindle detection through amplitude-frequency normal modelling.

Nonclercq A, Urbain C, Verheulpen D, Decaestecker C, Van Bogaert P, Peigneux P.

J Neurosci Methods. 2013 Apr 15;214(2):192-203. doi: 10.1016/j.jneumeth.2013.01.015. Epub 2013 Jan 28.

PMID:
23370313
34.

Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies.

Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, Rodriguez A, Johnson BD, Megalizzi V, Decaestecker C, Laurent G, Saussez S.

J Cancer Res Clin Oncol. 2013 May;139(5):727-37. doi: 10.1007/s00432-013-1375-7. Epub 2013 Jan 25.

PMID:
23354841
35.

EFTUD2 haploinsufficiency leads to syndromic oesophageal atresia.

Gordon CT, Petit F, Oufadem M, Decaestecker C, Jourdain AS, Andrieux J, Malan V, Alessandri JL, Baujat G, Baumann C, Boute-Benejean O, Caumes R, Delobel B, Dieterich K, Gaillard D, Gonzales M, Lacombe D, Escande F, Manouvrier-Hanu S, Marlin S, Mathieu-Dramard M, Mehta SG, Simonic I, Munnich A, Vekemans M, Porchet N, de Pontual L, Sarnacki S, Attie-Bitach T, Lyonnet S, Holder-Espinasse M, Amiel J.

J Med Genet. 2012 Dec;49(12):737-46. doi: 10.1136/jmedgenet-2012-101173.

PMID:
23188108
36.

Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas.

Kindt N, Lechien J, Decaestecker C, Rodriguez A, Chantrain G, Remmelink M, Laurent G, Gabius HJ, Saussez S.

Anticancer Res. 2012 Oct;32(10):4499-505.

PMID:
23060578
37.

A simplified approach for the molecular classification of glioblastomas.

Le Mercier M, Hastir D, Moles Lopez X, De Nève N, Maris C, Trepant AL, Rorive S, Decaestecker C, Salmon I.

PLoS One. 2012;7(9):e45475. doi: 10.1371/journal.pone.0045475. Epub 2012 Sep 18.

38.

Clustering methods applied in the detection of Ki67 hot-spots in whole tumor slide images: an efficient way to characterize heterogeneous tissue-based biomarkers.

Lopez XM, Debeir O, Maris C, Rorive S, Roland I, Saerens M, Salmon I, Decaestecker C.

Cytometry A. 2012 Sep;81(9):765-75. doi: 10.1002/cyto.a.22085. Epub 2012 Jun 22.

39.

Human papillomavirus DNA strongly correlates with a poorer prognosis in oral cavity carcinoma.

Duray A, Descamps G, Decaestecker C, Remmelink M, Sirtaine N, Lechien J, Ernoux-Neufcoeur P, Bletard N, Somja J, Depuydt CE, Delvenne P, Saussez S.

Laryngoscope. 2012 Jul;122(7):1558-65. doi: 10.1002/lary.23298. Epub 2012 Apr 24.

PMID:
22532307
40.

Cells lacking β-actin are genetically reprogrammed and maintain conditional migratory capacity.

Tondeleir D, Lambrechts A, Müller M, Jonckheere V, Doll T, Vandamme D, Bakkali K, Waterschoot D, Lemaistre M, Debeir O, Decaestecker C, Hinz B, Staes A, Timmerman E, Colaert N, Gevaert K, Vandekerckhove J, Ampe C.

Mol Cell Proteomics. 2012 Aug;11(8):255-71. doi: 10.1074/mcp.M111.015099. Epub 2012 Mar 22.

41.

Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer.

Ferdinande L, Decaestecker C, Verset L, Mathieu A, Moles Lopez X, Negulescu AM, Van Maerken T, Salmon I, Cuvelier CA, Demetter P.

Br J Cancer. 2012 Jan 3;106(1):141-7. doi: 10.1038/bjc.2011.513. Epub 2011 Nov 22.

42.

A new method to address unmet needs for extracting individual cell migration features from a large number of cells embedded in 3D volumes.

Adanja I, Megalizzi V, Debeir O, Decaestecker C.

PLoS One. 2011;6(7):e22263. doi: 10.1371/journal.pone.0022263. Epub 2011 Jul 15.

43.

High incidence of high-risk HPV in benign and malignant lesions of the larynx.

Duray A, Descamps G, Arafa M, Decaestecker C, Remmelink M, Sirtaine N, Ernoux-Neufcoeur P, Mutijima E, Somja J, Depuydt CE, Delvenne P, Saussez S.

Int J Oncol. 2011 Jul;39(1):51-9. doi: 10.3892/ijo.2011.1031. Epub 2011 May 4.

PMID:
21573490
44.

Quantitative immunohistochemical fingerprinting of adhesion/growth-regulatory galectins in salivary gland tumours: divergent profiles with diagnostic potential.

Remmelink M, de Leval L, Decaestecker C, Duray A, Crompot E, Sirtaine N, André S, Kaltner H, Leroy X, Gabius HJ, Saussez S.

Histopathology. 2011 Mar;58(4):543-56. doi: 10.1111/j.1365-2559.2011.03776.x.

PMID:
21410745
45.

Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma.

Cludts S, Decaestecker C, Johnson B, Lechien J, Leroy X, Kindt N, Kaltner H, André S, Gabius HJ, Saussez S.

Anticancer Res. 2010 Sep;30(9):3313-9.

PMID:
20944103
46.

Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.

Le Calvé B, Rynkowski M, Le Mercier M, Bruyère C, Lonez C, Gras T, Haibe-Kains B, Bontempi G, Decaestecker C, Ruysschaert JM, Kiss R, Lefranc F.

Neoplasia. 2010 Sep;12(9):727-39. Erratum in: Neoplasia. 2011 Sep;13(9):5 p following 886.

47.

TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas.

Rorive S, Lopez XM, Maris C, Trepant AL, Sauvage S, Sadeghi N, Roland I, Decaestecker C, Salmon I.

Mod Pathol. 2010 Oct;23(10):1418-28. doi: 10.1038/modpathol.2010.136. Epub 2010 Aug 6.

48.

Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy.

Megalizzi V, Le Mercier M, Decaestecker C.

Med Res Rev. 2012 Mar;32(2):410-27. doi: 10.1002/med.20218. Epub 2010 Aug 4. Review.

PMID:
20687157
49.

In vitro antiprotozoal, antimicrobial and antitumor activity of Pavetta crassipes K. Schum leaf extracts.

Baldé ES, Megalizzi V, Traoré MS, Cos P, Maes L, Decaestecker C, Pieters L, Baldé AM.

J Ethnopharmacol. 2010 Aug 9;130(3):529-35. doi: 10.1016/j.jep.2010.05.042. Epub 2010 May 31.

PMID:
20561931
50.

Aristolochic acid nephropathy revisited: a place for innate and adaptive immunity?

Pozdzik AA, Berton A, Schmeiser HH, Missoum W, Decaestecker C, Salmon IJ, Vanherweghem JL, Nortier JL.

Histopathology. 2010 Mar;56(4):449-63. doi: 10.1111/j.1365-2559.2010.03509.x.

PMID:
20459552

Supplemental Content

Loading ...
Support Center